Literature DB >> 16518875

Proteomic analysis of nasal cells from cystic fibrosis patients and non-cystic fibrosis control individuals: search for novel biomarkers of cystic fibrosis lung disease.

Mónica Roxo-Rosa1, Gonçalo da Costa, Theo M Luider, Bob J Scholte, Ana V Coelho, Margarida D Amaral, Deborah Penque.   

Abstract

Potential biological markers for cystic fibrosis (CF) lung disease were identified by comparative proteomics profiling of nasal cells from deletion of phenylalanine residue 508 (F508del)-homozygous CF patients and non-CF controls. From the non-CF 2-DE gels, 65 spots were identified by MS, and a reference 2-DE map was thus established. The majority of those correspond to ubiquitously expressed proteins. Consistent with the epithelial origin of this tissue, some of the identified proteins are epithelial markers (e.g. cytokeratins, palate lung and nasal epithelium clone protein (PLUNC), and squamous cell carcinoma antigen 1). Comparison of this protein profile with the one similarly obtained for CF nasal cells revealed a set of differentially expressed proteins. These included proteins related to chronic inflammation and some others involved in oxidative stress injury. Alterations were also observed in the levels of cytoskeleton proteins, being probably implicated with cytoskeleton organization changes described to occur in CF-airways. Lower levels were found for some mitochondrial proteins suggesting an altered mitochondrial metabolism in CF. Differential expression was also found for two more enzymes that have not been previously associated to CF. Further studies will clarify the involvement of such proteins in CF pathophysiology and whether they are targets for CF therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16518875     DOI: 10.1002/pmic.200500273

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  30 in total

1.  Antimicrobial activity of PLUNC protects against Pseudomonas aeruginosa infection.

Authors:  Lina Lukinskiene; Yang Liu; Susan D Reynolds; Chad Steele; Barry R Stripp; George D Leikauf; Jay K Kolls; Y Peter Di
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

Review 2.  Redox balance in cystic fibrosis.

Authors:  Assem G Ziady; Jason Hansen
Journal:  Int J Biochem Cell Biol       Date:  2014-03-20       Impact factor: 5.085

3.  Identification of the SPLUNC1 ENaC-inhibitory domain yields novel strategies to treat sodium hyperabsorption in cystic fibrosis airway epithelial cultures.

Authors:  Carey A Hobbs; Maxime G Blanchard; Omar Alijevic; Chong Da Tan; Stephan Kellenberger; Sompop Bencharit; Rui Cao; Mehmet Kesimer; William G Walton; Ashley G Henderson; Matthew R Redinbo; M Jackson Stutts; Robert Tarran
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-10-11       Impact factor: 5.464

Review 4.  Bactericidal/Permeability-increasing protein fold-containing family member A1 in airway host protection and respiratory disease.

Authors:  Clemente J Britto; Lauren Cohn
Journal:  Am J Respir Cell Mol Biol       Date:  2015-05       Impact factor: 6.914

5.  Short palate, lung, and nasal epithelial clone-1 is a tightly regulated airway sensor in innate and adaptive immunity.

Authors:  Clemente J Britto; Qing Liu; David R Curran; Bhargavi Patham; Charles S Dela Cruz; Lauren Cohn
Journal:  Am J Respir Cell Mol Biol       Date:  2013-06       Impact factor: 6.914

Review 6.  Mammalian short palate lung and nasal epithelial clone 1 (SPLUNC1) in pH-dependent airway hydration.

Authors:  Robert Tarran; Matthew R Redinbo
Journal:  Int J Biochem Cell Biol       Date:  2014-03-13       Impact factor: 5.085

7.  Serum protein profiling of adults and children with Crohn disease.

Authors:  Anna Vaiopoulou; Maria Gazouli; Aggeliki Papadopoulou; Athanassios K Anagnostopoulos; George Karamanolis; George E Theodoropoulos; Amosy M'Koma; George T Tsangaris
Journal:  J Pediatr Gastroenterol Nutr       Date:  2015-01       Impact factor: 2.839

8.  Proteomic interaction profiling reveals KIFC1 as a factor involved in early targeting of F508del-CFTR to degradation.

Authors:  Sara Canato; João D Santos; Ana S Carvalho; Kerman Aloria; Margarida D Amaral; Rune Matthiesen; André O Falcao; Carlos M Farinha
Journal:  Cell Mol Life Sci       Date:  2018-07-31       Impact factor: 9.261

Review 9.  Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations.

Authors:  L Keith Scott; Robert Toner
Journal:  Lung       Date:  2017-06-16       Impact factor: 2.584

10.  Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways.

Authors:  Alaina L Garland; William G Walton; Raymond D Coakley; Chong D Tan; Rodney C Gilmore; Carey A Hobbs; Ashutosh Tripathy; Lucy A Clunes; Sompop Bencharit; M Jackson Stutts; Laurie Betts; Matthew R Redinbo; Robert Tarran
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.